NASDAQ:AMRN

Amarin (AMRN) Stock Forecast, Price & News

$0.93

+0.02 (+2.21%)

(As of 09/22/2023 ET)

Compare

Today's Range: $0.89
▼
$0.94
50-Day Range: $0.91
▼
$1.43
52-Week Range: $0.89
▼
$2.23

Volume: 1.42 million shs
Average Volume: 3.15 million shs
Market Capitalization: $373.83 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.81

Amarin MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 95.8% Upside
$1.81 Price Target
Short Interest: Healthy
4.09% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.20
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$312,000 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.22) to ($0.20) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

545th out of 968 stocks

Pharmaceutical Preparations Industry

242nd out of 445 stocks

3.0

Analyst's Opinion

Consensus Rating
Amarin has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $1.81, Amarin has a forecasted upside of 95.8% from its current price of $0.93.
Amount of Analyst Coverage
Amarin has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.09% of the outstanding shares of Amarin have been sold short.
Short Interest Ratio / Days to Cover
Amarin has a short interest ratio ("days to cover") of 6.7.
Change versus previous month
Short interest in Amarin has recently decreased by 9.54%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Amarin does not currently pay a dividend.
Dividend Growth
Amarin does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AMRN.

1.0

News and Social Media Coverage

News Sentiment
Amarin has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Amarin this week, compared to 2 articles on an average week.
Search Interest
Only 6 people have searched for AMRN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Amarin to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amarin insiders have bought more of their company's stock than they have sold. Specifically, they have bought $312,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 8.81% of the stock of Amarin is held by insiders.
Percentage Held by Institutions
Only 25.51% of the stock of Amarin is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Amarin are expected to grow in the coming year, from ($0.22) to ($0.20) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amarin is -10.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amarin is -10.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Amarin has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Amarin (NASDAQ:AMRN) Stock

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

AMRN Price History

30 days | 90 days | 365 days | Advanced Chart

AMRN Stock News Headlines

September 22, 2023 | americanbankingnews.com

FY2023 EPS Estimates for Amarin Co. plc (NASDAQ:AMRN) Cut by Zacks Research

September 20, 2023 | finance.yahoo.com

Amarin (NASDAQ:AMRN) Is In A Good Position To Deliver On Growth Plans

September 22, 2023 | Stansberry Research (Ad)

New gold-backed currency could kill the Dollar

Rumors are circulating of a new currency that will be backed by gold. A huge story, if true. And while it’s impossible to know how it will pan out, there’s one important move you should make right now, before this happens. It’s the best way to protect your wealth today. Because if you’re not careful, YOU could be the one who pays the price

September 12, 2023 | finance.yahoo.com

Amarin to Present at the 2023 Cantor Global Healthcare Conference

August 31, 2023 | msn.com

Amarin Corp - ADR (AMRN) Price Target Increased by 35.17% to 2.50

August 8, 2023 | finance.yahoo.com

Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel

August 7, 2023 | benzinga.com

Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)

August 7, 2023 | finanznachrichten.de

Amarin Corporation plc: Scottish Medicines Consortium Accepts VAZKEPA (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland

September 22, 2023 | Stansberry Research (Ad)

New gold-backed currency could kill the Dollar

August 3, 2023 | finance.yahoo.com

Amarin (AMRN) Q2 Earnings and Revenues Surpass Estimates

August 3, 2023 | finance.yahoo.com

Amarin Reports Second Quarter 2023 Financial Results

August 2, 2023 | finanznachrichten.de

Amarin Corporation plc: Amarin Reports Second Quarter 2023 Financial Results

July 31, 2023 | finance.yahoo.com

Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea

July 27, 2023 | finance.yahoo.com

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

July 25, 2023 | finance.yahoo.com

Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain

July 21, 2023 | msn.com

Goldman Sachs Maintains Amarin Corp - ADR (AMRN) Sell Recommendation

July 20, 2023 | finanznachrichten.de

Amarin Corporation plc: Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt

July 20, 2023 | seekingalpha.com

Amarin appoints Patrick Holt CEO

July 20, 2023 | msn.com

Northland Capital Markets Maintains Amarin Corp - ADR (AMRN) Market Perform Recommendation

July 20, 2023 | finance.yahoo.com

Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt

July 19, 2023 | finance.yahoo.com

Amarin (AMRN) Dips 16% on Layoff Plan & Preliminary Sales Miss

July 19, 2023 | markets.businessinsider.com

Why Are Amarin Shares Plunging Today?

July 19, 2023 | msn.com

Amarin Tanks as it Plans Reorganization

July 18, 2023 | seekingalpha.com

Amarin sinks 11% on plan to undergo restructuring

July 18, 2023 | finanznachrichten.de

Amarin Corporation plc: Amarin Appoints Patrick Holt as President and Chief Executive Officer

July 18, 2023 | markets.businessinsider.com

Amarin Corp Appoints Patrick Holt As President And CEO

July 18, 2023 | finance.yahoo.com

Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally

See More Headlines

Receive AMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

AMRN Company Calendar

Last Earnings: 8/02/2023
Today: 9/22/2023
Next Earnings (Estimated): 10/26/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AMRN
CUSIP: N/A
CIK: 897448
Web: www.amarincorp.com
Phone: (531) 669-9020
Fax: N/A
Employees: 365
Year Founded: 1991

Price Target and Rating

Average Stock Price Forecast: $1.81
High Stock Price Forecast: $3.00
Low Stock Price Forecast: $1.00
Forecasted Upside/Downside: +95.8%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.09)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-105,800,000.00
Net Margins: -11.06%
Pretax Margin: -12.44%
Return on Equity: -6.56%
Return on Assets: -4.36%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.61
Quick Ratio: 1.77

Sales & Book Value

Annual Sales: $369.19 million
Price / Sales: 1.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.47 per share
Price / Book: 0.63

Miscellaneous

Outstanding Shares: 403,830,000
Free Float: 368,252,000
Market Cap: $373.83 million
Optionable: Optionable
Beta: 1.76

Social Links

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Thomas Charles Reilly (Age 51)
Chief Financial Officer
Comp: $856.49k

Dr. Steven B. Ketchum Ph.D. (Age 58)
Pres of R&D and Chief Scientific Officer
Comp: $991.19k

Mr. Aaron D. Berg (Age 60)
Exec. VP & Pres of U.S.
Comp: $913.7k

Mr. Patrick Holt
Pres, CEO & Director

Mr. Jordan Zwick (Age 36)
Sr. VP of Corp. Bus. Devel. & Investor Relations

Ms. Donna Pasek
Sr. VP of HR

Mr. Laurent Abuaf
Pres of Europe & Sr. VP

Dr. Nabil Abadir
Chief Medical Officer of Global Medical Affairs

Dr. David Keenan Ph.D.
Exec. VP of Technical Operations & Pres of Europe

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AMRN Stock - Frequently Asked Questions

Should I buy or sell Amarin stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRN, but not buy additional shares or sell existing shares.
View AMRN analyst ratings or view top-rated stocks.
What is Amarin's stock price forecast for 2023?: 3 equities research analysts have issued twelve-month price objectives for Amarin's stock. Their AMRN share price forecasts range from $1.00 to $3.00. On average, they anticipate the company's stock price to reach $1.81 in the next year. This suggests a possible upside of 95.8% from the stock's current price.
View analysts price targets for AMRN or view top-rated stocks among Wall Street analysts.
How have AMRN shares performed in 2023?: Amarin's stock was trading at $1.21 on January 1st, 2023. Since then, AMRN stock has decreased by 23.5% and is now trading at $0.9257.
View the best growth stocks for 2023 here.
Are investors shorting Amarin?: Amarin saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 16,500,000 shares, a drop of 9.5% from the August 15th total of 18,240,000 shares. Based on an average daily trading volume, of 2,450,000 shares, the days-to-cover ratio is currently 6.7 days.
View Amarin's Short Interest.
When is Amarin's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our AMRN earnings forecast.
How were Amarin's earnings last quarter?: Amarin Co. plc (NASDAQ:AMRN) released its earnings results on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.04). The biopharmaceutical company earned $80.17 million during the quarter, compared to analysts' expectations of $73.40 million. Amarin had a negative net margin of 11.06% and a negative trailing twelve-month return on equity of 6.56%.
What is John Thero's approval rating as Amarin's CEO?: 43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com. John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend.
What other stocks do shareholders of Amarin own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

What is Amarin's stock symbol?: Amarin trades on the NASDAQ under the ticker symbol "AMRN."
Who are Amarin's major shareholders?: Amarin's stock is owned by a number of retail and institutional investors. Top institutional investors include ExodusPoint Capital Management LP (0.96%), Woodline Partners LP (0.56%), Price Jennifer C. (0.55%), Gratus Capital LLC (0.46%), Acadian Asset Management LLC (0.29%) and AlphaCentric Advisors LLC (0.14%). Insiders that own company stock include David M Stack, John F Thero, Joseph S Zakrzewski, Michael Wayne Kalb, Olsen Per Wold, Patrick Holt and Steven B Ketchum.
View institutional ownership trends.
How do I buy shares of Amarin?: Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Amarin's stock price today?: One share of AMRN stock can currently be purchased for approximately $0.93.
How much money does Amarin make?: Amarin (NASDAQ:AMRN) has a market capitalization of $373.83 million and generates $369.19 million in revenue each year. The biopharmaceutical company earns $-105,800,000.00 in net income (profit) each year or ($0.09) on an earnings per share basis.
How many employees does Amarin have?: The company employs 365 workers across the globe.
Does Amarin have any subsidiaries?: The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.
Read More
How can I contact Amarin?: Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The official website for the company is www.amarincorp.com. The biopharmaceutical company can be reached via phone at (531) 669-9020 or via email at investor.relations@amarincorp.com.

This page (NASDAQ:AMRN) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial